Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment
Launched by ASTRAZENECA · Apr 13, 2010
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of informed consent
- • Patients known or newly diagnosed with GERD or patients with typical symptoms of GERD- heartburn, regurgitation (in the last case, GerdQ sum score should be ≥8, in the absence of PPI treatment)
- Exclusion Criteria:
- • Any symptoms at visit 1 suggesting a need for further investigation, judged by the Investigator (alarm symptoms).The alarm symptoms suggesting complicated disease are: dysphagia, odynophagia, bleeding, weight loss without intention or anemia.
- • Previous participation in the present study
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brasov, , Romania
Bucharest, , Romania
Galati, , Romania
Iasi, , Romania
Timisoara, , Romania
Tg. Mures, , Romania
Pitesti, , Romania
Arad, , Romania
Sibiu, , Romania
Targoviste, , Romania
Braila, , Romania
Buzau, , Romania
Ploiesti, , Romania
Bacau, , Romania
Cluj, , Romania
Slatina, , Romania
Rm. Valcea, , Romania
Floresti, , Romania
Vanatori(gl), , Romania
Patients applied
Trial Officials
CRISTINA TEODORESCU
Study Director
AstraZeneca Pharma SRL Romania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials